Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells

Cancer Research

Volumn 59, Issue 23, 1999, Pages 5938-5946

  Brangi, Mariafiorella ^a   Litman, Thomas ^a   Ciotti, Marco ^b   Nishiyama, Kenryu ^a   Kohlhagen, Glenda ^a   Takimoto, Chris ^a   Robey, Robert ^a   Pommier, Yves ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; IRINOTECAN; TOPOTECAN;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; COLON CANCER; CONFOCAL MICROSCOPY; DRUG TRANSPORT; ENZYME ACTIVITY; GENE EXPRESSION; GLUCURONIDATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL SURVIVAL; DNA DAMAGE; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSCOPY, CONFOCAL; MITOXANTRONE; POLYMERASE CHAIN REACTION; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0033429542     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dean, M., and Allikmets, R. Evolution of ATP-binding cassette transporter genes. Curr. Opin. Genet. Dev., 5: 779-785, 1995.
2. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., and Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.
3. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.
4. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
5. Rothenberg, M. L. Topoisomerase 1 inhibitors: review and update. Ann. Oncol., 8: 837-855, 1997.
6. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
7. Hoki, Y., Fujimori, A., and Pommier, Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol., 40: 433-438, 1997.
8. Yang, C. J., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
9. Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., and Schellens, J. H. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br. J. Cancer, 77: 1645-1652, 1998.
10. Takahashi, T., Fujiwara, Y., Yamakido, M., Katoh, O., Watanabe, H., and Mackenzie, P. I. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn. J. Cancer Res., 88: 1211-1217, 1997.
11. de Bruin, M., Miyake, K., Litman, T., Robey, R., and Bates S. Reversal of resistance by GF120918 in cell lines expressing the new ABC half-transporter, MXR. Cancer Letters, in press, 1999.
12. Morris, R. G., Kotasek, D., and Paltridge, G. Disposition of epirubicin and metabolites with repeated courses to cancer patients. Eur. J. Clin. Pharmacol., 40: 481-487, 1991.
13. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
14. Blanz, J., Mewes, K., Ehninger, G., Proksch, B., Greger, B., Waidelich, D., and Zeller, K. P. Isolation and structure elucidation of urinary metabolites of mitoxantrone. Cancer Res., 51: 3427-3433, 1991.
15. Burchell, B., Ebner, T., Baird, S., Bin Senafi, S., Clarke, D., Brierley, C., and Sutherland, L. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity. Environ. Health Perspect., 102 (Suppl. 9): 19-23, 1994.
16. Burchell, B., Baird, S., and Coughtrie, M. W. H. The role of xenobiotic glucuronidating enzymes in drug resistance of tumor tissues and cells. In: L. Ernster (ed.), Xenobiotics and cancer, pp. 263-275. London: Taylor & Francis, 1991.
17. Meech, R., and Mackenzie, P. I. Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum. Arch. Biochem. Biophys., 356: 77-85, 1998.
18. Oude Elferink, R. P., and Jansen, P. L. The role of the canalicular multispecific organic anion transporter in the disposal of endo-and xenobiotics. Pharmacol. Ther., 64: 77-97, 1994.
19. Zhang, X. P., Ritke, M. K., Yalowich, J. C., Slovak, M. L., Ho, J. P., Collins, K. I., Annable, T., Arceci, R. J., Durr, F. E., and Greenberger, L. M. P-Glycoprotein mediates profound resistance to bisantrene. Oncol. Res., 6: 291-301, 1994.
20. Rabindran, S. K., He, H., Singh, M., Brown, E., Collins, K. I., Annable, T., and Greenberger, L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 58: 5850-5858, 1998.
21. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
22. Zhan, Z., Sandor, V. A., Gamelin, E., Regis, J., Dickstein, B., Wilson, W., Fojo, A. T., and Bates, S. E. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood, 89: 3795-3800, 1997.
23. Meech, R., and Mackenzie, P. I. Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol., 24: 907-915, 1997.
24. 14C]glucuronic acid. Anal. Biochem., 109: 321-329, 1980.
25. Ritter, J. K., Sheen, Y. Y., and Owens, I. S. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells: 3,4-catechol estrogens and estriol as primary substrates. J. Biol. Chem., 265: 7900-7906, 1990.
26. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase 1. Cancer Res., 49: 5016-5022, 1989.
27. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase 1 inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
28. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA repair: a laboratory manual of research procedures, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
29. Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., and Pommier, Y. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J. Med. Chem., 41: 2216-2226, 1998.
30. Wang, L. F., Ting, C. Y., Lo, C. K., Su, J. S., Mickley, L. A., Fojo, A. T., Whang-Peng, J., and Hwang, J. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res., 57: 1516-1522, 1997.
31. Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., Fournel-Gigleux, S., Green, M., Hum, D. W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Chowdhury, J. R., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. F., and Nebert, D. W. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7: 255-269, 1997.
32. Rivory, L. P., and Robert, J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother. Pharmacol., 36: 176-179, 1995.
33. Sharom, F. J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol., 160: 161-175, 1997.
34. Muller, M., Meijer, C., Zaman, G. J. R., Borst, P., Scheper, R. J., Mulder, N. H., deVries, E. G. E., and Jansen, P. L. M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 91: 13033-13037, 1994.
35. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1993.
36. Loe, D. W., Deeley, R. G., and Cole, S. P. Characterization of vincristine transport by the M, 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res., 58: 5130-5136, 1998.
37. Rappa, G., Lorico, A., Flavell, R. A., and Sartorelli, A. C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res., 57: 5232-5237, 1997.
38. Rosing, H., van Zomeren, D. M., Doyle, E., Bult, A., and Beijnen, J. H. O-Glucuronidation, a newly identified metabolic pathway for topotecan and N-des-raethyl topotecan. Anticancer Drugs, 9: 587-592, 1998.
39. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., and Cvitkovic, E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol., 8: 1049-1051, 1997.
40. Gessner, T., Vaughan, L. A., Beehler, B. C., Bartels, C. J., and Baker, R. M. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res., 50: 3921-3927, 1990.
41. Rekha, G. K., and Sladek, N. E. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother. Pharmacol., 40: 215-224, 1997.
42. Franklin, T. J., Jacobs, V., Jones, G., Ple, P., and Bruneau, P. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res., 56: 984-987, 1996.
43. Mojarrabi, B., and Mackenzie, P. I. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem. Biophys. Res. Commun., 247: 704-709, 1998.
44. Knutsen, T., Rao, V. K., Reid, T., Mickley, L., Schneider, E., Miyake, K., Ghadimi, B. M., Padilla-Nash, H., Pack, S., Greenberger, L., Cowan, K., Dean, M., Fojo, T., and Bates, S. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer, in press, 1999.